Sandbox/table: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{|
The following table contains the main risk factors for CDI:<ref name="pmid22146873">{{cite journal| author=Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ| title=Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. | journal=J Antimicrob Chemother | year= 2012 | volume= 67 | issue= 3 | pages= 742-8 | pmid=22146873 | doi=10.1093/jac/dkr508 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22146873  }} </ref><ref name="KnightSurawicz2013">{{cite journal|last1=Knight|first1=Christopher L.|last2=Surawicz|first2=Christina M.|title=Clostridium difficile Infection|journal=Medical Clinics of North America|volume=97|issue=4|year=2013|pages=523–536|issn=00257125|doi=10.1016/j.mcna.2013.02.003}}</ref><ref name="Planche2013">{{cite journal|last1=Planche|first1=Tim|title=Clostridium difficile|journal=Medicine|volume=41|issue=11|year=2013|pages=654–657|issn=13573039|doi=10.1016/j.mpmed.2013.08.003}}</ref><ref name="KnightSurawicz2013">{{cite journal|last1=Knight|first1=Christopher L.|last2=Surawicz|first2=Christina M.|title=Clostridium difficile Infection|journal=Medical Clinics of North America|volume=97|issue=4|year=2013|pages=523–536|issn=00257125|doi=10.1016/j.mcna.2013.02.003}}</ref><ref name="KnightSurawicz2013">{{cite journal|last1=Knight|first1=Christopher L.|last2=Surawicz|first2=Christina M.|title=Clostridium difficile Infection|journal=Medical Clinics of North America|volume=97|issue=4|year=2013|pages=523–536|issn=00257125|doi=10.1016/j.mcna.2013.02.003}}</ref>
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #A1BCDD; text-align: center;">
<font color="#FFF">
'''Peritonitis '''
</font>
</div>


<div class="mw-customtoggle-table1" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;">
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
<font color="#FFF">
! style="width: 500px;background: #4479BA"|{{fontcolor|#FFF| '''''Severity of the disease'''''}}
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Primary Spontaneous Bacterial'''''
</font>
</div>
 
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table1" style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Primary Spontaneous Bacterial }}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="width: 120px;background: #F5F5F5"| Mild: diarrhea as the only symptom
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 2 gm IV q8h (q4h, if life-threatening infection) '''''<BR> OR <BR>▸'''''[[Ticaricillin Clavulanate]] 3.1 gm IV q6h '''''<BR> OR <BR>▸'''''[[Piperacillin Tazobactam]] 3.375 gm IV q6h (or 4-hour infusion of 3.375 gm q8h)'''''<BR> OR <BR>▸'''''[[Ceftriaxone]] 2 gm IV q24h'''''<BR> OR <BR>▸'''''[[Ertapenem]] 1 gm IV q24h'''''
| style="width: 120px;background: #DCDCDC"| Moderate:  raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''If resistant [[E. coli]] or [[Klebsiella]] species'''''
| style="width: 120px;background: #F5F5F5"| Severe: leucocytosis >15,000 cells/mL OR serum creatinene level >1.5 times baseline or abdominal tenderness and serum albumin < 3 g/dL
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]] 500 mg IV q6h '''''<BR> OR <BR>▸'''''[[Meropenem]] 1000 mg IV q8h'''''<BR> OR <BR>▸'''''[[Doripenem]] 500 mg IV q8h (1 hr infusion)'''''
| style="width: 120px;background: #DCDCDC"| Severe complicated: hypotension or shock, ileus, megacolon, leucocytosis >20,000 cells/mL OR leucopenia <2,000, lactate >2.2 mmol/L, delirium, fever ≥ 38.5 °C, organ failure
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | ''''' If checking sensitivities, then start'''''
|}
 
 
 
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
! style="width: 300px;background: #4479BA"|{{fontcolor|#FFF| '''''Community-onset infection '''''}}
! style="width: 300px;background: #4479BA"|{{fontcolor|#FFF| '''''Hospital-onset infection '''''}}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 mg IV q12h'''''<BR> OR <BR>▸'''''[[Levofloxacin]] 750 mg IV once daily'''''<BR> OR <BR>▸'''''[[Moxifloxacin]] 400 mg IV once daily'''''
| style="width: 120px;background: #F5F5F5"| Includes patients with 1 or more of the following conditions:
*The presence of an invasive device at time of admission
*History of [[MRSA]] infection or colonization
*History of surgery, hospitalization, [[dialysis]], or residence in a long-term care facility in the previous 12 months.
|  style="width: 120px;background: #F5F5F5"| Includes patients with positive culture results obtained >48 h after admission. <br> Patients might also have 1 of the conditions described in community-onset infection.
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''In addition to antibiotic, to decrease frequency of renal impairment start'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''IV [[Albumin]] 1.5 gm/kg at diagnosis and 1 gm/kg on day 3 '''''
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preventive regimen for chronic ascites'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[TMP-SMX-DS]] 1 tab po 5 days/week'''''<BR> OR <BR>▸'''''[[Ciprofloxacin]] 750 mg po once/week'''''
|-
|}
|}
|}
|}

Revision as of 17:25, 16 June 2014

The following table contains the main risk factors for CDI:[1][2][3][2][2]

Severity of the disease
Mild: diarrhea as the only symptom
Moderate: raised white cell count but <15,000 cells/mL and serum creatine <1.5 times baseline
Severe: leucocytosis >15,000 cells/mL OR serum creatinene level >1.5 times baseline or abdominal tenderness and serum albumin < 3 g/dL
Severe complicated: hypotension or shock, ileus, megacolon, leucocytosis >20,000 cells/mL OR leucopenia <2,000, lactate >2.2 mmol/L, delirium, fever ≥ 38.5 °C, organ failure


Community-onset infection Hospital-onset infection
Includes patients with 1 or more of the following conditions:
  • The presence of an invasive device at time of admission
  • History of MRSA infection or colonization
  • History of surgery, hospitalization, dialysis, or residence in a long-term care facility in the previous 12 months.
Includes patients with positive culture results obtained >48 h after admission.
Patients might also have 1 of the conditions described in community-onset infection.
  1. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ (2012). "Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics". J Antimicrob Chemother. 67 (3): 742–8. doi:10.1093/jac/dkr508. PMID 22146873.
  2. 2.0 2.1 2.2 Knight, Christopher L.; Surawicz, Christina M. (2013). "Clostridium difficile Infection". Medical Clinics of North America. 97 (4): 523–536. doi:10.1016/j.mcna.2013.02.003. ISSN 0025-7125.
  3. Planche, Tim (2013). "Clostridium difficile". Medicine. 41 (11): 654–657. doi:10.1016/j.mpmed.2013.08.003. ISSN 1357-3039.